Nektar’s long-term alopecia results Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 20 April, 2026

Discover the latest trends, challenges, and strategies shaping the future of patient experience across 80+ companies. sponsored by Courier Health

presented by This Founder Could­n't Find His Own Clin­i­cal Tri­al. Now He's En­rolling Hun­dreds of Pa­tients for Phar­ma's Biggest Names

news KRAS drugmakers take another, better swing at lung cancer Novo Nordisk’s sickle cell therapy hits in Phase 3, but data lag expectations Nektar’s long-term mid-stage alopecia data fuels Phase 3 plans Odyssey Therapeutics will try again to IPO, this time in a warmer market UCB plots epilepsy expansion with $650M Neurona cell therapy acquisition

Apr 28 12:30 pm ET Connection ≠ continuity: Rethinking long-term evidence in the age of tokenization sponsored by PicnicHealth Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

in case you missed it 1. How expensive would a Revolution Medicines buyout be after its Phase 3 win? 2. Q&A: On IPO day, Kailera CEO Ron Renaud talks about obesity market, China and biotech sentiment 3. New CDC pick is lauded by public health pros, lamented by vaccine skeptics 4. Peer Review Novartis' Vas Narasimhan heads to Anthropic's board; Metsera alum joins Structure as COO 5. Biovac gets $108M backing for vaccine factory in South Africa 6. Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests 7. Where US science has been hit hardest after Trump’s first year 8. Indian weight-loss market becomes ‘bloodbath’ as drugmakers pile in